Introduction
Intravenous (IV) injection of antibiotics may be difficult in some cases or patient subsettings. Subcutaneous (SC) route offers several advantages over IV injection. It is painless and less associated with infectious and thrombotic complications. This route of administration is easy to perform at home or in institution and may avoid hospitalisation. The SC route is well established as a method of delivering hydration [1] [2] [3] , and to manage pain or discomfort in palliative care or in case of poor IV access [4, 5] . However, Fonzo-Christe et al. in a survey of SC drug use, underlined the lack of information regarding safety and efficacy [6] . The SC route is frequently used to deliver antibiotic therapy in France. In a previous observational study, 96% of French interviewed geriatricians and infectious diseases (ID) physicians declared to use this route for antibiotics, especially in case of unavailable oral, IV or intramuscular (IM) routes, during palliative care or to facilitate hospital discharge [7] .
Still, data on tolerance through this route of administration are lacking for many antibiotic drugs.
We performed an observational study to describe the modalities and adverse effects (AE) associated with SC antibiotics, and investigate risk factors associated with the latter.
Methods
This prospective, observational, multicentre study included every patient (≥18 years old) treated at least one day with SC antibiotics from May to September 2014, and followed up until the end of the antibiotic treatment. This study was conducted by the French ID (SPILF) and geriatric (SFGG) societies network and approved by the Institutional ethics committee of Poitiers University Hospital. Electronic mailing lists of the SPILF and SFGG were used to recruit the investigators. Physicians could include up to 10 patients, with a maximum of five patients treated with ceftriaxone in order to obtain reports with other antibiotic as well. Anonymous reports were completed through an online questionnaire using Modalisa ® software (Kynos, Paris, France). Sociodemographic characteristics of patients, reasons to chose SC route, type of infection and details of prescription practices were recorded. Occurrence of local (pain, erythema, induration and haematoma) and systemic AE were prospectively collected until the end of the treatment. Parameters associated with AE were assessed by univariate and multivariate analysis. Parameters achieving a P value of <0.05 in univariate analysis were entered into the multivariate logistic regression model. Clinical efficacy was investigated by asking physicians whether the infection was considered cured. In the absence of previous data providing estimates of the prevalence of adverse events, a minimum sample size of 200 patients was required to estimate a minimum 10% prevalence with 95% confidence and 5% precision (using SAS Proc Power exact computations).
Results

Population
Two hundred-nineteen patients were included by 66 investigators from 50 French centres; mean age was 83 ± 12.5 (range 19-104), and 56.9% were females. Patients were recruited in acute geriatric (n = 90, 41.1%), ID or internal medicine (n = 50, 22.9%) departments, in rehabilitation centres (n = 37, 17.0%) and in long term care facilities (n = 42, 19.3%). Ten were out-patients. One hundred and fifty-five patients (70.8%) were concomitantly treated with antithrombotic agents: prophylactic (n = 35, 22.5%) or curative (n = 7, 4.5%) low molecular weight heparin, vitamin K antagonists (n = 40, 30.3%), new oral anticoagulants (n = 6, 3.8%), acetylsalicylic acid (n = 27, 17.4%) or an association of both anticoagulant and antithrombotic agent (n = 40, 25.8%).
Infectious episodes
The source of infection was known in 201 cases (92%). Urinary (n = 96, 43.8%), respiratory (n = 72, 32.8%), bone and joint infections (n = 15, 6.8%) and digestive (n = 13, 5.9%) tract infections were the most prevalent. Sepsis was reported as severe in 14 (6.0%) patients.
Subcutaneous administration
Ceftriaxone, ertapenem and teicoplanin were the most frequent antibiotics reported, in 74.4%, 13.7% and 4.6% of cases, respectively (Table 1) . Ceftriaxone was administered subcutaneously at the dose of 1 g in 91.9% of cases. The other reported antibiotics were pipericillin/tazobactam, imipenem, amikacine, gentamicin, cefepime, ceftazidime and metronidazole administered in 16 patients (7.3%). In 48.8% of cases, the SC route was used after the start of antibiotic therapy through IV or oral route. Poor venous access (n = 128, 58.4%), palliative care decision (n = 71, 32.4%), patient's agitation (n = 46, 21.0%), contra-indicated oral (n = 45, 20.5%) and IM (n = 15, 6.8%) routes and absence of active oral antibiotic drug (n = 45, 20.5%) were the main SC indications, sometimes concurrent. The SC route was also used to facilitate hospital discharge in 46 patients (21.0%) or to avoid hospitalisation in 17 (7.8%).
The duration of antibiotic treatment ranged between one and 208 days. Thirty-five patients received SC antibiotic less than five days and 55 patients over 10 days. The median length of treatment (25th, 75th interquartiles) for ceftriaxone, ertapenem and teicoplanin was 9 (7, 10) days, 10 (7, 72) days and 28 (21, 42) days, respectively.
Adverse effects
Overall, 74 AE were reported in 50 patients (22.8%), receiving ceftriaxone (21.5%), ertapenem (23.3%), teicoplanin (70%) and gentamycin (one patient) ( Table 2 ). Most of AE were local (90.0%) ( Table 1 ). In 21 cases (42.0%), AE appeared after the first administration and most of patients presented AE within seven days of SC treatment (n = 40, 80.0%). Pain was the most reported local AE (13.2%), and no skin necrosis was recorded ( the use of ceftriaxone (n = 1), ertapenem (n = 2) and teicoplanin (n = 2). Two AE were considered to be severe: one patient treated with teicoplanin suffered from acute renal failure despite adequate drug level monitoring. This patient required extended hospitalisation. The other patient was given ceftriaxone and was readmitted thereafter because of persistent induration and pain at the injection site. Class of administered antibiotic (p = 0.004), rapid antibiotic infusion (< 5 min) (p = 0.028) and use of rigid catheter, subcutaneous needle or butterfly needle (p = 0.002), were significantly associated with AE (Table 2 ). If we do not include data with teicoplanin and rigid catheters, only 20 patients (9.1%) would have reported an adverse effect. Antithrombotic treatments were not associated with the incidence of AE: acetylsalicylic acid (p = 0.1), prophylactic heparin (p = 0.2), curative anticoagulation (p = 0.3), association of both anticoagulant and antithrombotic agent (p = 0.7). Lidocaine was used in 30% of cases and tended to decrease the occurrence of AE, but not significantly (p = 0.097). Logistic regression showed that the class of antibiotic (p = 0.002) and the use of rigid catheter (p = 0.009) were independently associated with AE.
Efficacy
SC antibiotic treatment was stopped as scheduled in 84.8% of cases; however, SC treatment was switched to another administration route in 23 patients and because of treatment failure in 16 patients. At the end of the treatment, 11 deaths were reported, 88.9% of patients were considered cured and 11 (5.5%) had a persisting infection.
Discussion
The SC route represents a valuable alternative in the elderly, particularly as shown in palliative and end-of-life care [8] . SC administration of antibiotics is rare in many countries but common in France. Still few data regarding the tolerance and the modalities of administration are reported.
The present study documents AE associated with SC administration of antibiotics in routine practice. The most often subcutaneously administered antibiotic was ceftriaxone, which is representative to our daily practice. AE were frequent (50 patients, 22.8%) and mostly occurred within the first week of the treatment. However, AE were local and mild without the need for withdrawing the antibiotic course in most of the cases.
SC treatments can lead to severe local AE, like necrosis especially with aminoglycosides [9] [10] [11] [12] [13] , ceftriaxone [14] and ertapenem [15] , particularly when administered with a rapid infusion. However, we did not observe such a complication in the present study. AE was independently related to the use of rigid catheters like subcutaneous and butterfly needles. Conversely, concomitant prescription of antithrombotics did not influence the occurrence of AE. Adjunction of lidocaine tented to decrease AE occurrence but not significantly. Pragmatically, slowing infusion rate to over 5 min duration, and use of non-rigid catheters would seem sensible for those using subcutaneous antibiotics. SC teicoplanin administration could be very useful especially to manage infection requiring long treatment courses (for instance bone and joint infection due to methicillin resistant-Staphylococcus aureus). Our study found a high level of AE. The number of patients included (n = 10) limits any definitive statement and more studies are needed regarding the occurrence of AE and the usefulness of lidocain as well.
The first reason to use SC route is likely the presence of poor venous access. Central venous catheter or peripherally inserted central catheters (Picc) are possible options for IV administration of antibiotics but difficult to plan in a short period of time and associated with a higher infectious complications rate than SC route [16] . Indeed, we did not experience any infectious complication with SC route in our study. Moreover central venous catheters are usually inappropriate in palliative care.
Subcutaneous administration of antibiotics may be also useful when treating patients with hyperactive delirium secondary to infection, preventing the need for physical restraint or use of hypnotics, which expose to other complications as well.
The SC route could be particularly interesting for the treatment of infections that require long treatment courses. Ferry et al., described the use of SC ertapenem as salvage therapy for difficult-to-treat bone and joint infections with a mean treatment duration around 90 days without any local AE [17] .
The SC route could especially fit in with 'time dependent killing antibiotic'. In fact, the area under the curve (AUC) and the time over the minimal inhibitory concentration are quite similar between IV and SC routes [18] , as illustrated by Frasca et al. [19] . These promising results regarding pharmacokinetics strengthen the need to explore this technique.
Finally, SC route may be useful in reducing the length of stay or in avoiding hospitalisation itself. This option may have beneficial consequences on quality of life and healthcare cost.
This study has one major limitation: the intensity of the local AE was not assessed through validated scales; however, very few cases required dedicated care and the majority of local AE were mild.
In conclusion, SC antibiotic administration is associated with frequent, though benign local AE. It could be a valuable alternative to IV route especially in the elderly with behavioural disturbance or poor venous accesses. Pharmacokinetic and efficacy studies are needed to better assess the advantages of this practice.
Key points
• Poor venous access and palliative care are the main reasons to deliver antibiotic subcutaneously (SC).
• Local adverse effects (pain, induration, erythema and haematoma) are frequent (23% of cases) but mild.
• Non-rigid catheter appears protective against adverse effect.
• SC route could be an interesting and safe alternative to intravenous route to deliver antibiotics, especially in Geriatrics.
